Evidence map›Paper›PMID 34541481›Full record

ArticleEClinicalMedicine2021

Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China.

Yaping Wang, Ruchong Chen, Fengyu Hu, Yun Lan, Zhaowei Yang, Chen Zhan, Jingrong Shi, Xizi Deng, Mei Jiang, Shuxin Zhong and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Yaping WangGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Ruchong ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Fengyu HuGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Yun LanGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Zhaowei YangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Chen ZhanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Jingrong ShiGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Xizi DengGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Mei JiangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Shuxin ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Baolin LiaoGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Kai DengGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Jingyan TangGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Liliangzi GuoGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Mengling JiangGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Qinghong FanGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Meiyu LiGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Jinxin LiuGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Yaling ShiGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Xilong DengGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Xincai XiaoGuangzhou Chest Hospital, Guangzhou Medical University, Guangzhou 510095, China.
Min KangGuangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
Yan LiGuangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
Weijie GuanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Yimin LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Shiyue LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Feng LiGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.
Nanshan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Laboratory, Bio-Island, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Xiaoping TangGuangzhou Eighth People's Hospital , Guangzhou Medical University, Guangzhou, 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA novel variant of SARS-CoV-2, the Delta variant of concern (VOC, also known as lineage B.1.617.2), is fast becoming the dominant strain globally. We reported the epidemiological, viral, and clinical characteristics of hospitalized patients infected with the Delta VOC during the local outbreak in Guangzhou, China.

methodsWe extracted the epidemiological and clinical information pertaining to the 159 cases infected with the Delta VOC across seven transmission generations between May 21 and June 18, 2021. The whole chain of the Delta VOC transmission was described. Kinetics of viral load and clinical characteristics were compared with a cohort of wild-type infection in 2020 admitted to the Guangzhou Eighth People's Hospital.

findingsThere were four transmission generations within the first ten days. The Delta VOC yielded a significantly shorter incubation period (4.0 vs. 6.0 days), higher viral load (20.6 vs. 34.0, cycle threshold of the ORF1a/b gene), and a longer duration of viral shedding in pharyngeal swab samples (14.0 vs. 8.0 days) compared with the wild-type strain. In cases with critical illness, the proportion of patients over the age of 60 was higher in the Delta VOC group than in the wild-type strain (100.0% vs. 69.2%,

interpretationInfection with the Delta VOC is characterized by markedly increased transmissibility, viral loads and risk of disease progression compared with the wild-type strain, calling for more intensive prevention and control measures to contain future outbreaks.

fundingNational Grand Program, National Natural Science Foundation of China, Guangdong Provincial Department of Science and Technology, Guangzhou Laboratory.

Indexed as

COVID-19Delta variantRisk factorTransmission

Identifiers

PMID34541481
PMCPMC8435265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.